Big Pharma Turns to China for Innovative Drug Development
Major Western pharmaceutical companies are increasingly turning to China's biotechnology sector to source innovative drug candidates, marking a significant shift in the global industry landscape. Historically viewed as a manufacturer of generic drugs and ingredients, China has rapidly evolved into a leader in cutting-edge molecular biology and biomedical research. A prime example of this trend is Pfizer, which recently paid $1.25 billion to Chinese firm 3SBio for rights to a promising cancer drug candidate. This strategic move highlights how China's biotech startups are outpacing Western counterparts in speed and cost-efficiency while developing treatments for critical conditions like cancer and obesity. Pfizer CEO Albert Bourla acknowledged the unprecedented level of innovation emerging from China, signaling that the country is no longer just a market for selling Western medicines but a primary hub for original drug discovery. This transition threatens to overturn the traditional dynamic where the West led research and the East provided manufacturing, positioning China as a dominant force in future pharmaceutical advancements.
Wire timeline
Big Pharma Turns to China for Innovative Drug Development
Major Western pharmaceutical companies are increasingly turning to China's biotechnology sector to source innovative drug candidates, marking a significant shift in the global industry landscape. Historically viewed as a manufacturer of generic drugs and ingredients, China has rapidly evolved into a leader in cutting-edge molecular biology and biomedical research. A prime example of this trend is Pfizer, which recently paid $1.25 billion to Chinese firm 3SBio for rights to a promising cancer drug candidate. This strategic move highlights how China's biotech startups are outpacing Western counterparts in speed and cost-efficiency while developing treatments for critical conditions like cancer and obesity. Pfizer CEO Albert Bourla acknowledged the unprecedented level of innovation emerging from China, signaling that the country is no longer just a market for selling Western medicines but a primary hub for original drug discovery. This transition threatens to overturn the traditional dynamic where the West led research and the East provided manufacturing, positioning China as a dominant force in future pharmaceutical advancements.
WSJ.com: US Business